IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients

International Journal of Cancer

Volumn 139, Issue 4, 2016, Pages 869-881

  Sudam Patil, Rushikesh ^a   Umesh Shah, Sagar ^a   Vinayak Shrikhande, Shailesh ^b   Goel, Mahesh ^b   Prabhakar Dikshit, Rajesh ^a   Vivek Chiplunkar, Shubhada ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Department of Surgical Oncology ^*  (India)

Author keywords

Th17; Treg; T 17; vascular endothelial growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; GALLBLADDER CANCER; GALLBLADDER CANCER CELL LINE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLARIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SURVIVAL ANALYSIS; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84976583442     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30134     Document Type: Article

References (50)

1. Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012; 27:642–53.
2. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118:1591–602.
3. Shrikhande SV, Barreto SG, Singh S, et al. Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause!. Eur J Surg Oncol 2010; 36:514–9.
4. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4:695–706.
5. Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. The Oncologist 2010; 15:168–81.
6. Sirohi B, Mitra A, Jagannath P, et al. Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer. Future Oncol 2015; 11:1501–9.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883–99.
8. Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity 2011; 34:149–62.
9. Wilke C, Zou W. TH17 cells in the tumor micro-environment. In: Jiang S, ed. TH17 cells in health and diseaseed. New York: Springer, 2011. 481–96.
10. Patil RS, Bhat SA, Dar AA, et al. The Jekyll and Hyde story of IL17-producing gammadeltaT Cells. Front Immunol 2015; 6:37
11. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1–7.
12. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636–45.
13. Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol 2014;95:723–31.
14. Yamada N, Chung Y, Ohtani H, et al. Establishment and characterization of a new human gallbladder carcinoma cell line (OCUG-1) producing TA-4. Int J Oncol 1997; 10:1251–5.
15. Ganjalikhani Hakemi M, Ghaedi K, Andalib A, et al. Optimization of human Th17 cell differentiation in vitro: evaluating different polarizing factors. In Vitro Cell Dev Biol Animal 2011; 47:581–92.
16. Caccamo N, La Mendola C, Orlando V, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood 2011; 118:129–38.
17. Fisher JP, Heuijerjans J, Yan M, et al. gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 2014; 3:e27572
18. Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat Rev Immunol 2015; 15:683–91.
19. Dhar S, Chiplunkar SV. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vgamma9Vdelta2 T cells. Cancer Immun 2010; 10:10
20. Hannani D, Ma Y, Yamazaki T, et al. Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol 2012; 33:199–206.
21. Ye J, Ma C, Hsueh EC, et al. Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013; 190:2403–14.
22. Ma S, Cheng Q, Cai Y, et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 2014; 74:1969–82.
23. Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015; 522:345–8.
24. Zarogoulidis P, Katsikogianni F, Tsiouda T, et al. Interleukin-8 and interleukin-17 for cancer. Cancer Invest 2014; 32:197–205.
25. Cochaud S, Giustiniani J, Thomas C, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep 2013; 3:3456
26. Yamagiwa S, Gray JD, Hashimoto S, et al. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001; 166:7282–9.
27. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107:301–4.
28. Shibuya KC, Goel VK, Xiong W, et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014; 9:e96565
29. Valmori D, Raffin C, Raimbaud I, et al. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA 2010; 107:19402–7.
30. Nakayamada S, Takahashi H, Kanno Y, et al. Helper T cell diversity and plasticity. Curr Opin Immunol 2012; 24:297–302.
31. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J Clin Invest 2003; 112:1437–43.
32. Wu P, Wu D, Ni C, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40:785–800.
33. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234–43.
34. Zhang Y, Huang Y, Qin M. Tumour-infiltrating FoxP3+ and IL-17-producing T cells affect the progression and prognosis of gallbladder carcinoma after surgery. Scand J Immunol 2013; 78:516–22.
35. Oo YH, Banz V, Kavanagh D, et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 2012; 57:1044–51.
36. Kesselring R, Thiel A, Pries R, et al. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010; 103:1245–54.
37. Wakita D, Sumida K, Iwakura Y, et al. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 2010; 40:1927–37.
38. Ma J, Wang J, Fan W, et al. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol 2014; 7:246–54.
39. Klein RM, Bernstein D, Higgins SP, et al. SERPINE1 expression discriminates site-specific metastasis in human melanoma. Exp Dermatol 2012; 21:551–4.
40. Nijaguna MB, Patil V, Urbach S, et al. Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding protein 1 (IGFBP1) to promote angiogenesis. J Biol Chem 2015; 290:23401–15.
41. Sun XN, Cao WG, Wang X, et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol 2011; 32:1183–90.
42. Letelier P, Garcia P, Leal P, et al. Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma. Appl Immunohistochem Mol Morphol 2014; 22:530–6.
43. Bizama C, Garcia P, Espinoza JA, et al. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev 2015; 41:222–34.
44. Ghiringhelli F, Apetoh L. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J 2015; 38:111–6.
45. Ma Y, Aymeric L, Locher C, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491–503.
46. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
47. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in Psoriasis. N Engl J Med 2015; 373:1318–28.
48. Yang J, Sundrud MS, Skepner J, et al. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci 2014; 35:493–500.
49. Pere H, Tanchot C, Bayry J, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326–33.
50. Bayry J, Tartour E, Tough DF. Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends Pharmacol Sci 2014; 35:163–5.